WEE1 and Lewy body dementia: A randomized, placebo‐controlled study evaluating the safety and tolerability of bosutinib, another protein kinase inhibitor, in DLB started in 2019, and both plasma t‐α‐synuclein and o‐α‐synuclein were used as outcome measures (ClinicalTrials.gov identifier NCT03888222).